Prescription Required
Glyxambi 25mg/5mg Tablet 10s is a combination medicine that helps control blood sugar levels.
It is unsafe to consume alcohol with Glyxambi 25mg/5mg Tablet 10s.
Glyxambi 25mg/5mg Tablet 10s may be unsafe to use during pregnancy. Animal studies conducted so far have shown harmful effects of medicine on developing baby while limited human studies have conducted. Before prescribing it; doctor will weigh the potential risks and benefits associated with it.
Glyxambi 25mg/5mg Tablet 10s is probably unsafe to use during breastfeeding. Human studies conducted revealed that the drug can pass through the breastmilk and can harm the baby.
It is not known whether Glyxambi 25mg/5mg Tablet 10s alters the ability to drive. Avoid driving if you experience symtpoms that impact driving ability.
Glyxambi 25mg/5mg Tablet 10s should be used with caution in patients with kidney disease. Dose adjustment for the medicine may be required. Please consult your doctor. Use of Glyxambi 25mg/5mg Tablet 10s is contraindicated in patients with severe kidney disease or in dialysis.
Glyxambi 25mg/5mg Tablet 10s is safe to use in patients with liver disease. No dose adjustment of Glyxambi 25mg/5mg Tablet 10s is recommended. However, avoid the use if having severe hepatic impairment.
Empagliflozin (SGLT2 Inhibitor): Helps the kidneys remove excess sugar through urine, lowering blood glucose levels. Linagliptin (DPP-4 Inhibitor): Increases insulin secretion and reduces glucagon levels, helping control post-meal sugar spikes. Dual action results in better blood sugar control and reduced risk of heart and kidney complications.
Type 2 Diabetes Mellitus – A chronic condition where the body becomes resistant to insulin or doesn’t produce enough, leading to high blood sugar. Diabetic Nephropathy – A diabetes-related kidney complication caused by high blood sugar damaging kidney function. Cardiovascular Disease in Diabetes – People with diabetes have a higher risk of heart disease and stroke, making blood sugar control crucial.
Glyxambi 25/5mg Tablet is a dual-action diabetes medication containing Empagliflozin and Linagliptin. It helps control blood sugar, promotes weight loss, and reduces heart and kidney disease risks in Type 2 Diabetes patients.
MBA in pharmaceutical management
Content Updated on
Saturday, 8 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA